516 related articles for article (PubMed ID: 25900105)
1. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
[TBL] [Abstract][Full Text] [Related]
2. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.
Polinski JM; Mohr PE; Johnson L
Arthritis Rheum; 2009 Jun; 61(6):745-54. PubMed ID: 19479704
[TBL] [Abstract][Full Text] [Related]
3. Specialty Tier-Level Cost Sharing and Biologic Agent Use in the Medicare Part D Initial Coverage Period Among Beneficiaries With Rheumatoid Arthritis.
Doshi JA; Hu T; Li P; Pettit AR; Yu X; Blum M
Arthritis Care Res (Hoboken); 2016 Nov; 68(11):1624-1630. PubMed ID: 27014854
[TBL] [Abstract][Full Text] [Related]
4. Use and Spending for Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among US Medicare Beneficiaries.
Yazdany J; Tonner C; Schmajuk G
Arthritis Care Res (Hoboken); 2015 Sep; 67(9):1210-1218. PubMed ID: 25776035
[TBL] [Abstract][Full Text] [Related]
5. Coverage for hepatitis C drugs in Medicare Part D.
Jung JK; Feldman R; Cheong C; Du P; Leslie D
Am J Manag Care; 2016 May; 22(6 Spec No.):SP220-6. PubMed ID: 27266952
[TBL] [Abstract][Full Text] [Related]
6. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
7. Medicare Part D and Cost-Sharing for Antiretroviral Therapy and Preexposure Prophylaxis.
Tseng CW; Dudley RA; Chen R; Walensky RP
JAMA Netw Open; 2020 Apr; 3(4):e202739. PubMed ID: 32286656
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019.
Erath A; Dusetzina SB
JAMA Netw Open; 2020 Apr; 3(4):e203969. PubMed ID: 32338754
[TBL] [Abstract][Full Text] [Related]
9. Impact of Out-of-Pocket Costs on Prescription Fills Among New Initiators of Biologic Therapies for Rheumatoid Arthritis.
Hopson S; Saverno K; Liu LZ; AL-Sabbagh A; Orazem J; Costantino ME; Pasquale MK
J Manag Care Spec Pharm; 2016 Feb; 22(2):122-30. PubMed ID: 27015251
[TBL] [Abstract][Full Text] [Related]
10. Reducing out-of-pocket cost barriers to specialty drug use under Medicare Part D: addressing the problem of "too much too soon".
Doshi JA; Li P; Pettit AR; Dougherty JS; Flint A; Ladage VP
Am J Manag Care; 2017 Mar; 23(3 Suppl):S39-S45. PubMed ID: 29648739
[TBL] [Abstract][Full Text] [Related]
11. Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis.
Karaca-Mandic P; Joyce GF; Goldman DP; Laouri M
Health Serv Res; 2010 Oct; 45(5 Pt 1):1227-50. PubMed ID: 20831715
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
13. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
[TBL] [Abstract][Full Text] [Related]
14. Impact of Medicare Part D for Medicare-age adults with arthritis: prescription use, prescription expenditures, and medical spending from 2005 to 2008.
Cheng LI; Rascati KL
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1423-9. PubMed ID: 22508663
[TBL] [Abstract][Full Text] [Related]
15. Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs.
Hsu J; Fung V; Price M; Huang J; Brand R; Hui R; Fireman B; Newhouse JP
JAMA; 2008 Apr; 299(16):1929-36. PubMed ID: 18430912
[TBL] [Abstract][Full Text] [Related]
16. Coverage of New Drugs in Medicare Part D.
Naci H; Kyriopoulos I; Feldman WB; Hwang TJ; Kesselheim AS; Chandra A
Milbank Q; 2022 Jun; 100(2):562-588. PubMed ID: 35502786
[TBL] [Abstract][Full Text] [Related]
17. Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017.
Bartlett VL; Liu P; Dhruva SS; Shah ND; Bollinger KE; Ross JS
J Manag Care Spec Pharm; 2020 Apr; 26(4):562-567. PubMed ID: 32223594
[TBL] [Abstract][Full Text] [Related]
18. High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia.
Doshi JA; Li P; Huo H; Pettit AR; Kumar R; Weiss BM; Huntington SF
Am J Manag Care; 2016 Mar; 22(4 Suppl):s78-86. PubMed ID: 27270157
[TBL] [Abstract][Full Text] [Related]
19. Relationship of the use and costs of physician office visits and prescription drugs to travel distance and increases in member cost share.
Cecil WT; Barnes J; Shea T; Coulter SL
J Manag Care Pharm; 2006 Oct; 12(8):665-76. PubMed ID: 17269845
[TBL] [Abstract][Full Text] [Related]
20. Drug plan design incentives among Medicare prescription drug plans.
Huskamp HA; Keating NL; Dalton JB; Chernew ME; Newhouse JP
Am J Manag Care; 2014 Jul; 20(7):562. PubMed ID: 25295402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]